GLPGA Stock Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €32.19 |
52 Week High | €40.27 |
52 Week Low | €31.12 |
Beta | 0.071 |
1 Month Change | 0% |
3 Month Change | 3.42% |
1 Year Change | -24.47% |
3 Year Change | -63.29% |
5 Year Change | -63.81% |
Change since IPO | 179.87% |
Recent News & Updates
Recent updates
Shareholder Returns
GLPGA | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | -1.6% | -0.2% |
1Y | -24.5% | -29.6% | 0.8% |
Return vs Industry: GLPGA matched the UK Biotechs industry which returned -25.4% over the past year.
Return vs Market: GLPGA underperformed the UK Market which returned -5.4% over the past year.
Price Volatility
GLPGA volatility | |
---|---|
GLPGA Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: GLPGA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GLPGA's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 1,233 | Paul Stoffels | https://www.glpg.com |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Galapagos NV Fundamentals Summary
GLPGA fundamental statistics | |
---|---|
Market cap | €2.31b |
Earnings (TTM) | -€153.07m |
Revenue (TTM) | €543.97m |
4.2x
P/S Ratio-15.1x
P/E RatioIs GLPGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLPGA income statement (TTM) | |
---|---|
Revenue | €543.97m |
Cost of Revenue | €480.88m |
Gross Profit | €63.09m |
Other Expenses | €216.16m |
Earnings | -€153.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 22, 2024
Earnings per share (EPS) | -2.32 |
Gross Margin | 11.60% |
Net Profit Margin | -28.14% |
Debt/Equity Ratio | 0% |
How did GLPGA perform over the long term?
See historical performance and comparison